SHPHF (Sihuan Pharmaceutical Holdings Group) Piotroski F-Score: 7 (As of Jun. 25, 2026) — 17% Above Median


SHPHF Sihuan Pharmaceutical Holdings Group Ltd SHPHF
52 GF Score
Price $0.13
GF Value $0.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group Piotroski F-Score?

Sihuan Pharmaceutical Holdings Group SHPHF 52 Piotroski F-Score is 7 as of Jun. 25, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates SHPHF with a GF Scoreâ„¢ of 52/100 and a GF Valueâ„¢ of $0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 981 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 91.85% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sihuan Pharmaceutical Holdings Group has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's Piotroski F-Score or its related term are showing as below:

SHPHF' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of Sihuan Pharmaceutical Holdings Group was 7. The lowest was 3. And the median was 6.

Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sihuan Pharmaceutical Holdings Group Piotroski F-Score Related Terms


Sihuan Pharmaceutical Holdings Group Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sihuan Pharmaceutical Holdings Group's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group Piotroski F-Score Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 3.00 6.00 6.00 7.00

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 0.00 6.00 0.00 7.00

SHPHF vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Piotroski F-Score falls into.


SHPHF
52GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was $25.5 Mil.
Cash Flow from Operations was $-3.3 Mil.
Revenue was $371.7 Mil.
Gross Profit was $255.8 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (1446.498 + 1651.512) / 2 = $1549.005 Mil.
Total Assets at the begining of this year (Dec24) was $1,446.5 Mil.
Long-Term Debt & Capital Lease Obligation was $104.3 Mil.
Total Current Assets was $944.6 Mil.
Total Current Liabilities was $523.9 Mil.
Net Income was $-29.8 Mil.

Revenue was $261.1 Mil.
Gross Profit was $170.5 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (1615.561 + 1446.498) / 2 = $1531.0295 Mil.
Total Assets at the begining of last year (Dec23) was $1,615.6 Mil.
Long-Term Debt & Capital Lease Obligation was $104.3 Mil.
Total Current Assets was $785.3 Mil.
Total Current Liabilities was $454.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sihuan Pharmaceutical Holdings Group's current Net Income (TTM) was 25.5. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sihuan Pharmaceutical Holdings Group's current Cash Flow from Operations (TTM) was -3.3. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=25.513/1446.498
=0.01763777

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-29.758/1615.561
=-0.01841961

Sihuan Pharmaceutical Holdings Group's return on assets of this year was 0.01763777. Sihuan Pharmaceutical Holdings Group's return on assets of last year was -0.01841961. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sihuan Pharmaceutical Holdings Group's current Net Income (TTM) was 25.5. Sihuan Pharmaceutical Holdings Group's current Cash Flow from Operations (TTM) was -3.3. ==> -3.3 <= 25.5 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=104.296/1549.005
=0.06733096

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=104.305/1531.0295
=0.06812736

Sihuan Pharmaceutical Holdings Group's gearing of this year was 0.06733096. Sihuan Pharmaceutical Holdings Group's gearing of last year was 0.06812736. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=944.561/523.916
=1.80288634

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=785.304/454.684
=1.72714237

Sihuan Pharmaceutical Holdings Group's current ratio of this year was 1.80288634. Sihuan Pharmaceutical Holdings Group's current ratio of last year was 1.72714237. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sihuan Pharmaceutical Holdings Group's number of shares in issue this year was 9126.832. Sihuan Pharmaceutical Holdings Group's number of shares in issue last year was 9265.984. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=255.829/371.707
=0.68825446

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=170.548/261.116
=0.65315032

Sihuan Pharmaceutical Holdings Group's gross margin of this year was 0.68825446. Sihuan Pharmaceutical Holdings Group's gross margin of last year was 0.65315032. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=371.707/1446.498
=0.25697028

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=261.116/1615.561
=0.16162559

Sihuan Pharmaceutical Holdings Group's asset turnover of this year was 0.25697028. Sihuan Pharmaceutical Holdings Group's asset turnover of last year was 0.16162559. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sihuan Pharmaceutical Holdings Group has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Sihuan Pharmaceutical Holdings Group (SHPHF) has a Piotroski F-Score of 7 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Sihuan Pharmaceutical Holdings Group's Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #80 out of 981 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Sihuan Pharmaceutical Holdings Group's Piotroski F-Score too high?
Sihuan Pharmaceutical Holdings Group's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Sihuan Pharmaceutical Holdings Group's value of 7 is 40% above this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #80 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #80 out of 981 companies for Piotroski F-Score. This places Sihuan Pharmaceutical Holdings Group in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Sihuan Pharmaceutical Holdings Group's value of 7 is 40% above this benchmark. Historically, Sihuan Pharmaceutical Holdings Group's own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Sihuan Pharmaceutical Holdings Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.17, compared to a current price of $0.13 — trading 23.7% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Drug Manufacturers industry median of 5.00. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current Piotroski F-Score is 7 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $0.13 is trading 23.7% below its estimated GF Value™ of $0.17. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for SHPHF:

  • Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: $0.17 vs. price of $0.13 (23.7% below fair value)
  • GF Score™: 52/100 with 4 warning signs
  • Industry Position: 40% above the Drug Manufacturers median (#80 of 981)

No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score

Get the complete analysis for SHPHF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$0.17
GF Value